# Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

> **NCT06657209** · PHASE4 · RECRUITING · sponsor: **Stanford University** · enrollment: 104 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Diabetes
- Type 2 Diabetes
- Pre Diabetes

## Interventions

- **PROCEDURE:** Insulin resistance testing
- **PROCEDURE:** OGTT
- **PROCEDURE:** Fat biopsy
- **RADIATION:** DXA scan
- **PROCEDURE:** MRI
- **PROCEDURE:** 1H-MRS
- **DRUG:** Tirzepatide
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT06657209
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2027-12-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657209, "Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06657209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*